Biodexa PharmaceuticalsBDRX
13F holders, Q2 2025 (June 30)4holders −2
0new positions
2sold out
$0.86avg. 13F price*
At the end of Q2 2025, 4 institutions reported holding Biodexa Pharmaceuticals PLC (BDRX) in their 13F filings, down 2 from Q1 2025. 0 opened new positions and 2 sold out. The largest holders were GAMMA Investing LLC ($10K), SBI Securities Co., Ltd. ($5K) and UBS Group AG ($2K).
- Company
- Biodexa Pharmaceuticals PLC
- CUSIP
- 59564R807
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $977 |
All 13F filers, Q1 2025 → Q2 2025: 16,181 shares bought and 17,829 shares sold, net −1,648 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| GAMMA Investing LLC | 0.00% | Add +737.3% | 11,940 | $10K |
| SBI Securities Co., Ltd. | 0.00% | Add +566700.0% | 5,668 | $5K |
| UBS Group AG | 0.00% | Reduce -89.4% | 1,989 | $2K |
| Rhumbline Advisers | 0.00% | Reduce -78.1% | 69 | $59 |
"% of holder's portfolio" is BDRX's weight in each manager's 13F, not the share of Biodexa Pharmaceuticals PLC the manager owns.